Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus DYRENIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus DYRENIUM.
ALDACTONE vs DYRENIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Potassium-sparing diuretic; competitively inhibits sodium reabsorption in the distal renal tubule, reducing sodium-potassium exchange and increasing sodium and chloride excretion while retaining potassium.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
Oral: 100 mg twice daily. Maximum: 300 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Terminal elimination half-life approximately 24-72 hours (average 48 hours), prolonged in renal impairment; clinical context: supports once-daily dosing, but accumulation may occur with repeated dosing.
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Primarily renal (hepatic metabolism to active metabolites, then renal excretion); approximately 50% of the dose is excreted unchanged in urine; minor biliary/fecal elimination.
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic